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The large variety of microbial species in
the human microbiome plays an impor-
tant role in human health by affecting tissue
differentiation, modulation of the immune
system, as well as the general response
against infectious pathogens. The aryl
hydrocarbon receptor (AhR) contributes to
immune homeostasis as having an antimi-
crobial role on the one hand – owing to
AhR-dependent IL-22 transcription – and,
on the other, an anti-inflammatory role
in that it mediates the differentiation of
regulatory T cells (Tregs). Here, we have
examined the multifaceted physiological
role of AhR as resulting from the vast array
of recently described AhR ligands and of
the multiplicity of AhR-expressing cells in
host-microbial symbiosis in mammals.
THE PROMISCUOUS NATURE OF AhR
AGONISTS
Aryl hydrocarbon receptor is a ligand-
dependent transcription factor activated
by a variety of synthetic and natural
molecules. In particular, ligands of AhR
include hydrocarbons, heterocyclic amines,
and indole-derived compounds. Dioxin
(2,3,7,8-tetrachlorodibenzo-p-dioxin;
TCDD) represents the prototypical envi-
ronmental and most potent AhR ligand
known (1). In addition, a variety of herbal
extracts – such as ginseng, licorice, and
gingko biloba – stimulate AhR DNA bind-
ing and the downstream transcription
of numerous genes, thus indicating that
AhR might have evolved to respond to
mainly dietary products to which animals
and humans are chronically exposed (2).
Interestingly, ginseng, saponins (gingeno-
sides) have been defined as potent AhR
agonists or antagonists (3, 4). Despite the
ability of environmental chemicals or other
products in diet to bind and subsequently
activate AhR, former studies have also
shown that natural endogenous ligands
may bind and mediate AhR-dependent
downstream effects as well (5). Thus the
evolution of the AhR – some 450 million
years ago – underlies the concept that the
original AhR ligands emerged prior to
the anthropogenic introduction of pol-
yaromatic hydrocarbons (2). In addition,
AhR has an exceptionally promiscuous
ligand-binding pocket, which explains the
extreme variety of molecules binding AhR
with agonist or antagonistic activity (6).
Indeed, it has been shown that both biliru-
bin and biliverdin represent good examples
of endogenous ligands in liver with agonist
activity for AhR (7, 8). The induction of
AhR in the liver by those ligands induces
upregulation of Ugt1a1 to prevent jaun-
dice in neonates and to regulate antioxidant
AhR effects in the adult liver (9). The intri-
cacies of AhR activation also relate to the
mode of application of a ligand and not
only to its nature. Thus systemic adminis-
tration of 6-formylindolo [3,2-b]carbazole
(FICZ) reduced clinical signs in a murine
model of encephalomyelitis (EAE), while
local injection of FICZ, incorporated into
the antigen emulsion for induction of
EAE, seemed to more directly target and
promote Th17 cells, thereby exacerbating
pathology in EAE (10).
Recently, many studies have shown
that the microbiome represents a con-
sistent source of AhR endogenous lig-
ands with disparate effects on immune
homeostasis (Figure 1). Thus, moving
to the context of the microbiota, the
nature of both ligands and target cells
vary consistently according to the microbe
niche, providing a more complex sce-
nario of AhR’s impact on immune home-
ostasis. In the human skin, commensals
such as Malassezia yeasts secrete AhR ago-
nists, such as indirubin, FICZ, indolo[3,2-
b]carbazole (ICZ), malassezin, pityriac-
itrin, and tryptamine, which are all potent
AhR ligands (11). When skin extracts are
isolated from patients with ongoing skin
infection, AhR is potently activated, and
an increased concentration of AhR lig-
ands in the skin has been linked to the
development of Malassezia-associated skin
diseases. Interestingly, some of the iso-
lated molecules are able to convert to
other AhR ligands such as ICZ, which is
released under conversion of malassezin
(12). Therefore, Malassezia-derived AhR
ligands may have a significant impact
on skin homeostatic immune mechanisms
and disease development. Indeed, indiru-
bin and ICZ significantly augmented AhR-
mediated Cyp1a1 and Cyp1b1 gene expres-
sion in dendritic cells, while reducing Toll-
like receptor (TLR)-induced dendritic cell
maturation and T-lymphocyte prolifera-
tion (13). In line with this finding, FICZ
has been used to dampen the inflamma-
tory response in both mouse and human
skin (14). Through the activation of AhR in
non-hematopoietic skin cells, administra-
tion of FICZ ameliorated the inflammatory
profile of psoriasiform human and murine
skin specimens. Of interest, a key aspect of
tryptophan-derived metabolites is related
to their molecular dynamics of intercon-
version. For example, tryptamine serves
as a proligand for AhR, and its activation
depends mainly on monoamine oxidases
(15), which eventually convert tryptamine
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FIGURE 1 |Tryptophan-derived AhR activating molecules with antimicrobial activity.
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to other AhR ligands, such as the indole-3-
aldehyde (3-IAld) and eventually by spon-
taneous dimerization to FICZ (15). Impor-
tantly, intestinal microbiota will also con-
vert tryptophan to tryptamine by decar-
boxylation. In doing so, and by modulat-
ing the colonic ion secretion, tryptamine
affects the transit of food particles and bac-
terial cells through the gut lumen (16).
More recently, Pseudomonas aeruginosa as
well as Mycobacterium tuberculosis showed
an ability to activate AhR in the lung
through the release of pigmented virulence
factors, such as phenazines and phthiocol,
respectively, pointing to AhR as a sensor of
a new class of pathogen-associated molec-
ular patterns. Upon AhR binding, an AhR-
controlled metabolic circuit was activated
and the virulence factors degraded with
consequent pathogen clearance (17).
We found that highly adaptive lacto-
bacilli in the gut, in particular Lactobacillus
reuteri, by switching from sugar to tryp-
tophan as an energy source, were expanded
and produced an AhR ligand, 3-IAld, active
in innate lymphoid cells (ILCs) where it
would contribute to mucosal resistance
against the opportunistic pathogen Can-
dida albicans. IL-22 is the main down-
stream product of AhR activation upon
3-IAld stimulation in ILCs, regulating the
release of antimicrobial peptides in the gut
epithelia. Of notice, IL-22+ ILCs are also
able to limit segmented filamentous bac-
teria colonization in the gut (18). A sim-
ilar effect was found in the murine vagi-
nal tissue, where Lactobacillus acidophilus
will degrade tryptophan to 3-IAld and
protect mice from C. albicans vaginitis
(19). Pivotally, these antimicrobial effects
were more evident under conditions of
higher tryptophan availability in mucosal
tissues, as it occurs in mice fed with a
tryptophan-enriched diet or in mice bear-
ing deficiency of a tryptophan catabolic
enzyme.
In addition to microbial derived lig-
ands, mammalian cells in the liver, as
well as in peripheral lymph nodes, acti-
vate enzymes such as tryptophan-2,3-
dioxygenase (TDO2) and indoleamine-
2,3-dioxygenase 1 (IDO1), able to gen-
erate tryptophan derivatives such as
kynurenines, which also notably act as lig-
ands for AhR (6). Kynurenines have long
been known for their ability to exert spe-
cific antimicrobial activities (20). Thus,
the recent findings provide mechanistic
insight into the interplay between IDO1-
dependent metabolism and AhR activation
in colonization resistance and tolerance
induction at the host/microbe interface (6)
(Figure 1).
THE IDO1-AhR-TREG AXIS IN
MAMMALS: THE CO-EVOLUTION OF A
TOLEROGENIC DEFENSE STRATEGY
Humans have evolved with microbes, and
crucial factors for survival include prompt
recognition of invading pathogens, acqui-
sition of controlled immune response, fine-
tuned pathogen eradication and return
to homeostasis. Co-evolution with hosts
had a particularly strong impact on the
immune system, which needed to develop
an ability to discriminate between resident
microbes – maintaining a homeostatic bal-
ance – and invasive pathogens, which it
must respond to. This complexity could be
achieved by integrating two major immune
defense mechanisms: infection resistance
and disease tolerance (21). Induction of
immune tolerance and the maintenance
of homeostatic balance provide a series
of benefits, including avoidance of tissue
injury and para-inflammatory side effects,
such as chronic infection and inflamma-
tion, which are major epigenetic and envi-
ronmental factors that contribute to meta-
bolic diseases and autoimmunity, and, in
specific settings, to cancer. Conversely, the
induction of immune resistance reflects
opposite intents, such as the avoidance of
infection and control of microbial burden
(22, 23).
This paradigm has been epitomized
in fungal commensalisms where immune
protection must oppose fungal infectivity
and ensure survival, while limiting collat-
eral damage and restoring a homeostatic
environment (also referred to as“protective
tolerance”) (22, 24). Primordial resistance
against fungi is mainly mediated by nat-
urally occurring IL-22/IL-17A-producing
cells, highly prevalent at mucosal sites,
and activated by AhR (19, 25). The tryp-
tophan metabolic pathway appeared to
play a key and decisive role in foster-
ing tolerance by means of IDO1 activa-
tion, tryptophan starvation, the produc-
tion of immunomodulatory kynurenines,
and the activation of Tregs that are strictly
required for the generation of protec-
tive tolerance to fungi (26, 27). As AhR
activation leads to the activation of IDO1
(25), the regulatory loop involving AhR and
IDO1 may have driven the co-evolution
of commensal fungi with the mammalian
immune system and the microbiota, to
the benefit of host survival and fungal
commensalism.
More recently, the cross-regulatory cir-
cuit between IDO1 and AhR has been ele-
gantly shown to mediate disease tolerance
(6). Among IDO1 secondary metabolites,
l-kynurenine has been identified as an AhR
ligand (6). In turn, the AhR-associated Src
activity was responsible for IDO1 phos-
phorylation, TGF-β production, and Treg
cell expansion, thus allowing for endo-
toxin tolerance to occur. Importantly, the
activation of the IDO-AhR-Treg axis pre-
vented Salmonella typhimurium infection
and significantly reduced clinical signs of
Streptococcus arthritis (6).
More interestingly, the interaction
between IDO1 and AhR may have impor-
tant roles in the context of autoim-
mune diseases. Autoimmune diseases are
indeed multifactorial,depending on intrin-
sic or environmental components, includ-
ing diet, infections, and microbial expo-
sure. The role of AhR in autoimmunity is
even more interesting because of evidence
on protection to EAE by TCDD, which
exerts anti-inflammatory effects through
induction of Tregs (1). In this context, it is
interesting to note that FICZ also protects
against EAE when systemically adminis-
tered (10). Therefore, future studies are
needed to elucidate the possible role of AhR
ligands of microbial origin in protecting
from autoimmune diseases.
In conclusion, the development of a
highly specialized symbiosis requires iter-
ative sets of mutual adaptation between
and among symbionts and their hosts. This
demands moving beyond surveys of micro-
bial diversity to identify host/microbial
metabolites that directly target the IDO1-
AhR axis for the promotion of infection
control and immune homeostasis.
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